There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on BioCryst (BCRX – Research Report) and Asensus Surgical (ASXC – Research Report) with bullish sentiments.
BioCryst (BCRX)
H.C. Wainwright analyst Andrew Fein reiterated a Buy rating on BioCryst today and set a price target of $30.00. The company’s shares closed last Tuesday at $8.64, close to its 52-week low of $7.61.
According to TipRanks.com, Fein has 0 stars on 0-5 stars ranking scale with an average return of
Currently, the analyst consensus on BioCryst is a Moderate Buy with an average price target of $16.50, implying an 88.6% upside from current levels. In a report released yesterday, JMP Securities also reiterated a Buy rating on the stock with a $16.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Asensus Surgical (ASXC)
H.C. Wainwright analyst Swayampakula Ramakanth maintained a Buy rating on Asensus Surgical today and set a price target of $3.00. The company’s shares closed last Tuesday at $0.85, close to its 52-week high of $0.93.
According to TipRanks.com, Ramakanth is ranked 0 out of 5 stars with an average return of
Currently, the analyst consensus on Asensus Surgical is a Moderate Buy with an average price target of $3.00.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on BCRX:
- BioCryst Dives after Mixed Earnings
- BioCryst Reports Fourth Quarter and Full Year 2022 Financial Results and Upcoming Key Milestones
- BioCryst to Report Fourth Quarter 2022 Financial Results on February 21
- BioCryst reports inducement grants under Nasdaq listing rule
- BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
